Primary Approved Use
Lacosamide is FDA-approved as an adjunctive therapy for partial-onset (focal) seizures in patients aged 1 month and older, and for primary generalized tonic-clonic seizures in patients with epilepsy aged 4 years and older.[1]
How It Works in Epilepsy
It selectively enhances slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and reducing seizure spread. Clinical trials showed 40-50% median seizure reduction in focal epilepsy patients on 400 mg/day, outperforming placebo.[2]
Conditions with Strongest Evidence
Focal seizures respond best, with responder rates up to 41% in adults (vs. 22% placebo) across Phase 3 trials. It's less studied but effective for primary generalized tonic-clonic seizures, reducing frequency by 68% vs. 28% placebo.[1][2]
Drug-resistant focal epilepsy sees particular benefit, often combined with other anti-epileptics like levetiracetam or carbamazepine.
Off-Label and Emerging Uses
Some evidence supports use in status epilepticus (IV formulation), with 50-70% seizure cessation rates in small studies. Limited data exists for neuropathic pain, bipolar disorder, and status migrainosus, but efficacy is inconsistent and not FDA-approved.[3]
Who Responds Least or Has Risks
Patients with generalized epilepsy (non-tonic-clonic) or myoclonic seizures show weaker responses. Avoid in those with severe cardiac conduction issues due to PR interval prolongation risk. Common side effects include dizziness (25-31%), nausea (11-17%), and diplopia (11-19%).[1]
[1] FDA Label: Vimpat (lacosamide), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022253s044lbl.pdf
[2] Clinical Trials: SP667, SP754, SP755 (Biton et al., Epilepsia 2007; Chung et al., Lancet Neurol 2010)
[3] Review: Harden et al., CNS Drugs 2014